Approach to patients with heart failure and pulmonary hypertension

Current Treatment Options in Cardiovascular Medicine

Volumn 9, Issue 4, 2007, Pages 302-309

  Forfia, Paul R ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BOSENTAN; BRAIN NATRIURETIC PEPTIDE; CARDIOVASCULAR AGENT; CYCLIC GMP AGONIST; DARUSENTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LIVER ENZYME; LOOP DIURETIC AGENT; MILRINONE; NESIRITIDE; NITRIC OXIDE; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PROSTACYCLIN; SILDENAFIL; UNCLASSIFIED DRUG;

ARTERIAL PRESSURE; CARDIOMYOPATHY; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DOPPLER ECHOCARDIOGRAPHY; DRUG POTENTIATION; DRUG WITHDRAWAL; HEART ASSIST DEVICE; HEART CATHETERIZATION; HEART FAILURE; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART RIGHT VENTRICLE FUNCTION; HEART SURGERY; HUMAN; HYPERCAPNIA; HYPERTENSION; HYPOXEMIA; LOW DRUG DOSE; LUNG ARTERY PRESSURE; LUNG BLOOD FLOW; LUNG VASCULAR RESISTANCE; MITRAL VALVE REGURGITATION; MONOTHERAPY; NONHUMAN; PATHOPHYSIOLOGY; PULMONARY HYPERTENSION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; VASODILATATION; VENOUS PRESSURE;

EID: 34547554170     PISSN: 10928464     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11936-007-0025-2     Document Type: Review

References (53)

1. Drazner MH, Hamilton MA, Fonarow G, et al.: Relationship between right and left-sided filling pressures in 1000 patients with advanced heart failure. J Heart Lung Transplant 1999, 18:1126-1132.
2. Cappola TP, Felker GM, Kao WH, et al.: Pulmonary hypertension and risk of death in cardiomyopathy: patients with myocarditis are at higher risk. Circulation 2002, 105:1663-1668.
3. Stevenson WG, Stevenson LW, Middlekauff HR, et al.: Improving survival for patients with advanced heart failure a study of 737 consecutive patients. J Am Coll Cardiol 1995, 26:1417-1423.
4. Enriquez-Sarano M, Rossi A, Seward JB, et al.: Determinants of pulmonary hypertension in left ventricular dysfunction. J Am Coll Cardiol 1997, 29:153-159.
5. Tribouilloy CM, Enriquez-Sarano M, Rossi A, et al.: Determinants of the pulmonary artery pressure rise in left ventricular dysfunction. Cardiologia 1997, 42:1051-1058.
6. Tumminello G, Lancellotti P, Lempereur M, et al.: Determinants of pulmonary artery hypertension at rest and during exercise in patients with heart failure. Eur Heart J 2007, 28:569-574.
7. Butler J, Chomsky DB, Wilson JR: Pulmonary hypertension and exercise intolerance in patients with heart failure. J Am Coll Cardiol 1999, 34:1802-1806.
8. Delgado JF, Conde E, Sanchez V, et al.: Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure. Eur J Heart Fail 2005, 7:1011-1016.
9. Moraes DL, Colucci WS, Givertz MM: Secondary pulmonary hypertension in chronic heart failure: the role of the endothelium in pathophysiology and management. Circulation 2000, 102:1718-1723.
10. Ooi H, Colucci WS, Givertz MM: Endothelin mediates increased pulmonary vascular tone in patients with heart failure: demonstration by direct intrapulmonary infusion of sitaxsentan. Circulation 2002, 106:1618-1621.
11. Tsutamoto T, Kanamori T, Wada A, Kinoshita M: Uncoupling of atrial natriuretic peptide extraction and cyclic guanosine monophosphate production in the pulmonary circulation in patients with severe heart failure. J Am Coll Cardiol 1992, 20:541-546.
12. Black SM, Sanchez LS, Mata-Greenwood E, et al.: sGC and PDE5 are elevated in lambs with increased pulmonary blood flow and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2001, 281:L1051-L1057.
13. Zhao L, Mason NA, Morrell NW, et al.: Sildenafil inhibits hypoxia-induced pulmonary hypertension. Circulation 2001, 104:424-428.
14. Forfia PR, Lee M, Tunin RS, et al.: Acute phosphodiesterase 5 inhibition mimics hemodynamic effects of B-type natriuretic peptide and potentiates B-type natriuretic peptide effects in failing but not normal canine hearts. J Am Coll Cardiol 2007, 49:1079-1088.
15. Darze ES, Latado AL, Guimaraes AG, et al.: Incidence and clinical predictors of pulmonary embolism in severe heart failure patients admitted to a coronary care unit. Chest 2005, 128:2576-2580.
16. Ghio S: Pulmonary hypertension in advanced heart failure. Herz 2005, 30:311-317.
17. Di Salvo TG, Mathier M, Semigran MJ, Dec GW. Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure. J Am Coll Cardiol 1995, 25:1143-1153.
18. Ghio S, Gavazzi A, Campana C, et al.: Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure. J Am Coll Cardiol 2001, 37:183-188.
19. Ghio S, Recusani F, Klersy C, et al.: Prognostic usefulness of the tricuspid annular plane systolic excursion in patients with congestive heart failure secondary to idiopathic or ischemic dilated cardiomyopathy. Am J Cardiol 2000, 85:837-842.
20. Jessup M, Brozena S: Heart failure. N Engl J Med 2003, 348:2007-2018.
21. Rosario LB, Stevenson LW, Solomon SD, et al.: The mechanism of decrease in dynamic mitral regurgitation during heart failure treatment: importance of reduction in the regurgitant orifice size. J Am Coll Cardiol 1998, 32:1819-1824.
22. Levine HJ, Gaasch WH: Vasoactive drugs in chronic regurgitant lesions of the mitral and aortic valves. J Am Coll Cardiol 1996, 28:1083-1091.
23. Kizilbash AM, Willett DL, Brickner ME, et al.: Effects of afterload reduction on vena contracta width in mitral regurgitation. J Am Coll Cardiol 1998, 32:427-431.
24. Vinereanu D, Turner MS, Bleasdale RA, et al.: Mechanisms of reduction of mitral regurgitation by cardiac resynchronization therapy. J Am Soc Echocardiogr 2007, 20:54-62.
25. Karvounis HI, Dalamaga EG, Papadopoulos CE, et al.: Improved papillary muscle function attenuates functional mitral regurgitation in patients with dilated cardiomyopathy after cardiac resynchronization therapy. J Am Soc Ecbocardiogr 2006, 19:1150-1157.
26. Sutton MG, Plappert T, Hilpisch KE, et al.: Sustained reverse left ventricular structural remodeling with cardiac resynchronization at one year is a function of etiology: quantitative Doppler echocardiographic evidence from the Multicenter InSync Randomized Clinical Evaluation (MIRACLE). Circulation 2006, 113:266-272.
27. Califf RM, Adams KF, McKenna WJ, et al.: A randomized controlled trial of epoprostenol. therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST). Am Heart J 1997, 134:44-54.
28. Montalescot G, Drobinski G, Meurin P, et al.: Effects of prostacyclin on the pulmonary vascular tone and cardiac contractility of patients with pulmonary hypertension secondary to end-stage heart failure. Am J Cardiol 1998, 82:749-755.
29. Davie N, Haleen SJ, Upton PD, et al.: ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am J Respir Crit Care Med 2002, 165:398-405.
30. Cowburn PJ, Cleland JG, McDonagh TA, et al.: Comparison of selective ET(A) and ET(B) receptor antagonists in patients with chronic heart failure. Eur J Heart Fail 2005, 7:37-42.
31. Kelland NF, Webb DJ: Clinical trials of endothelin antagonists in heart failure: publication is good for the public health. Heart 2007, 93:2-4.
32. Anand I, McMurray J, Cohn JN, et al.: Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 2004, 364:347-354.
33. Fattouch K, Sbraga F, Bianco G, et al.: Inhaled prostacyclin nitric oxide, and nitroprusside in pulmonary hypertension after mitral valve replacement. J Card Surg 2005, 20:171-176.
34. Costard-Jackle A, Fowler MB: Influence of preoperative pulmonary artery pressure on mortality after heart transplantation: testing of potential reversibitity of pulmonary hypertension with nitroprusside is useful in defining a high risk group. J Am Coll Cardiol 1992, 19:48-54.
35. von Scheidt W, Costard-Jaeckle A, Stempfle HU, et al.: Prostaglandin E1 testing in heart failure-associated pulmonary hypertension enables transplantation: the PROPHET study. J Heart Lung Transplant 2006, 25:1070-1076.
36. Klotz S, Wenzelburger F, Stypmann J, et al.: Reversible pulmonary hypertension in heart transplant candidates: to transplant or not to transplant. Ann Thorac Surg 2006, 82:1770-1773.
37. Gavazzi A, Ghio S, Scelsi L, et al.: Response of the right ventricle to acute pulmonary vasodilation predicts the outcome in patients with advanced heart failure and pulmonary hypertension. Am Heart J 2003, 145:310-316.
38. Givertz MM, Hare JM, Loh E, et al.: Effect of bolus milrinone on hemodynamic variables and pulmonary vascular resistance in patients with severe left ventricular dysfunction: a rapid test for reversibility of pulmonary hypertension. J Am Coll Cardiol 1996, 28:1775-1780.
39. Loh E, Stamler JS, Hare JM, et al.: Cardiovascular effects of inhaled nitric oxide in patients with left ventricular dysfunction. Circulation 1994, 90:2780-2785.
40. Zimpfer D, Zrunek P, Sandner S, et al.: Post-transplant survival after lowering fixed pulmonary hypertension using left ventricular assist devices. Eur J Cardiothorac Surg 2007, 31:698-702.
41. Zimpfer D, Zrunek P, Roethy W, et al.: Left ventricular assist devices decrease fixed pulmonary hypertension in cardiac transplant candidates. J Thorac Cardiovasc Surg 2007, 133:689-695.
42. Ochiai Y, McCarthy PM, Smedira NG, et al.: Predictors of severe right ventricular failure after implantable left ventricular assist device insertion: analysis of 245 patients. Circulation 2002, 106(12 suppl 1):I198-I202.
43. Klodell CT Jr, Morey TE, Lobato EB, et al.: Effect of sildenafil on pulmonary artery pressure, systemic pressure, and nitric oxide utilization in patients with left ventricular assist devices. Ann Thorac Surg 2007, 83:68-71.
44. Corbin JD, Beasley A, Blount MA, Francis SH: High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors. Biochem Biopbys Res Commun 2005, 334:930-938.
45. Cohen AH, Hanson K, Morris K, et al.: Inhibition of cyclic 3′-5′-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. J Clin Invest 1996, 97:172-179.
46. Galie N, Ghofrani HA, Torbicki A, et al.: Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005, 353:2148-2157.
47. Gomez-Sanchez AM, De La Calzada SC, Subias EP, et al.: Pilot assessment of the response of several pulmonary hemodynamic variables to sublingual sildenafil in candidates for heart transplantation. Eur J Heart Fail 2004, 6:615-617.
48. Alaeddini J, Uber PA, Park MH, et al.: Efficacy and safety of sildenafil in the evaluation of pulmonary hypertension in severe heart failure. Am J Cardiol 2004, 94:1475-1477. severe PH with hemodynamic evidence of HF decompensation.
49. Lepore JJ, Maroo A, Bigatello LM, et al.: Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. Chest 2005, 127:1647-1653.
50. Klinger JR, Thaker S, Houtchens J, et al.: Pulmonary hemodynamic responses to brain natriuretic peptide and sildenafil in patients with pulmonary arterial hypertension. Chest 2006, 129:417-425.
51. Guazzi M, Tumminello G, Di Marco F, et al.: The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure. J Am Coll Cardiol 2004, 44:2339-2348.
52. Lewis GD, Lachmann J, Camuso J, et al.: Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure. Circulation 2007, 115:59-66.
53. Lewis GD, Shahzad K, Camuso J, et al.: Sildenafil therapy for systolic heart failure with secondary pulmonary hypertension: a randomized double-blind, placebo-controlled study [abstract]. J Card Fail 2006, 12(suppl 1):S70.